Oxford BioMedica: ocular focus

Country

United Kingdom

Oxford BioMedica Plc ended 2012 with a renewed focus on its gene-based therapies for eye diseases including advancing a collaboration with the Mayo Clinic to develop a treatment for chronic glaucoma. Revenue last year included a heavy contribution from ocular milestones.